This protocol applies to patients with acquired long QT syndrome in the specific context of Long QT syndrome type 3 (LQT3), a confirmed SCN5A pathogenic mutation, and a prolonged QT interval on 12-lead ECG — a genotype-defined sub-population with distinct management considerations.
In LQT3 patients, the SCN5A pathogenic mutation confers a specific electrophysiological substrate. When a prolonged QT interval is also present on ECG, this confirmed genotype–phenotype pairing identifies patients for whom genotype-specific therapy choices — beyond standard measures — become clinically relevant.
The structured regimen for this scenario centres on an intervention targeting the cardiac sympathetic nervous system. The complete protocol — eligibility criteria, clinical decision points, and the full management sequence — is available via the link below.